Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Post-COVID Syndrome and Tachycardia: Theoretical Base and Treatment Experience

https://doi.org/10.20996/1819-6446-2021-04-08

Full Text:

Abstract

The coronavirus pandemic showed not only an increase in levels of excess morbidity and mortality in the acute phase, but also persisting symptoms 4 weeks after the onset of the disease. A review of international studies on the prevalence and diversity of the manifestations of postcoid syndrome is presented. The data on such a manifestation of post-COVID syndrome as postural orthostatic tachycardia syndrome (POTS) are accumulating. Pathogenetic mechanisms, modern diagnostic criteria and research data on the prevalence of this syndrome are presented in the article. The Canadian Cardiovascular Society has proposed medications as a treatment for POTS, including the sinus node If channel inhibitor ivabradine. Data from several studies showing the effectiveness of this drug for POTS, including after suffering COVID-19, are presented in the article. Clinical data on the prevalence of tachycardia among patients admitted to the Sechenov University hospital are presented. About 18% of patients with hypertension and 21% of patients with normal blood pressure had a high heart rate. A clinical example of the use of ivabradine in a patient after a coronavirus infection is presented. Drug interactions and individual tolerance of ivabradine in patients after coronavirus infection are being discussed. The authors put forward the hypothesis about the further prospect of using ivabradine in the treatment of clinical manifestations of postcoid syndrome on the basis of literature data and their own experience.

About the Authors

V. I. Podzolkov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Valery I. Podzolkov - eLibrary SPIN 8683-2155

Moscow



A. E. Bragina
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Anna E. Bragina - eLibrary SPIN 3753-5539

Moscow



A. I. Tarzimanova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Aida I. Tarzimanova - eLibrary SPIN 2685-4078

Moscow



L. V. Vasil'eva
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Lubov V. Vasil'eva - eLibrary SPIN 9111-1333

Moscow



E. P. Batrakova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Elena P. Batrakova

Moscow



N. V. Lobova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Natalya V. Lobova

Moscow



E. E. Bykova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Ekaterina E. Bykova - eLibrary SPIN 8932-8731

Moscow



M. M. Khachuroeva
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Markha M. Khachuroeva

Moscow



References

1. Gupta A, Madhavan M, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat. Med. 2020;26:1017-32. DOI:10.1038/s41591-020-0968-3.

2. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220-32. DOI:10.1016/S0140-6736(20)32656-8.

3. Lee SH, Shin HS, Park HY, et al. Depression as a mediator of chronic fatigue and post-traumatic stress symptoms in Middle East respiratory syndrome survivors. Psychiatry Investig. 2019;16:59-64. DOI:10.30773/pi.2018.10.22.3.

4. Lee AM, Wong JGWS, McAlonan GM, et al. Stress and psychological distress among SARS survivors 1 year after the outbreak. Can J Psychiatry. 2007;52:233-40. DOI:10.1177/070674370705200405.

5. Chopra V, Flanders SA, O'Malley M, et al. Sixty-day outcomes among patients hospitalized with COVID- 19. Ann Intern Med. 2020;M20:5661. DOI:10.7326/M20-5661.

6. Carfi A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID-19. J Am Med Assoc. 2020;324:603-5. DOI:10.1001/jama.2020.12603.

7. Carvalho-Schneider C, Laurent E, Lemaignen A, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021;27:258-63. DOI:10.1016/j.cmi.2020.09.052.

8. Arnold DT, Hamilton FW, Milne A, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2020;76(4):399-401. DOI:10.1136/thoraxjnl-2020-216086.

9. Moreno-Perez O, Merino E, Leon-Ramirez JM, et al. Post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study. J Infect. 2021;82(3):378-83. DOI:10.1016/j.jinf.2021.01.004.

10. WHO. Emergency use ICD codes for COVID-19 disease outbreak. Available from: https://www.who.int/standards/classifications/classification-of-diseases/emergency-use-icd-codes-for-covid-19-disease-outbreak.

11. NICE. COVID-19 rapid guideline: managing the long-term effects of COVID-19. Available from: https://www.nice.org.uk/guidance/ng188/chapter/5-Management.

12. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021 Mar 22. DOI:10.1038/s41591-021-01283-z.

13. Raj SR, Guzman JC, Harvey P, et al. Canadian Cardiovascular society position statement on postural orthostatic tachycardia syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance. Canadian Journal of Cardiology. 2020;36(3):357-72. DOI:10.1016/j.cjca.2019.12.024.

14. Olshansky B, Cannom D, Fedorowski A, et al. Postural orthostatic tachycardia syndrome (POTS): a crit-ical assessment. Prog Cardiovasc Dis. 2020;63:263-70. DOI:10.1016/j.pcad.2020.03.010.

15. Johansson M, Stahlberg M, Runold M, et al. Long-Haul Post-COVID-19 Symptoms Presenting as a Variant of Postural Orthostatic Tachycardia Syndrome: The Swedish Experience. JACC Case Rep. 2021 Mar 10. DOI:10.1016/j.jaccas.2021.01.009.

16. Miglis MG, Prieto T, Shaik R. et al. A case report of postural tachycardia syndrome after COVID-19. Clin Auton Res 2020;30:449-451. DOI:10.1007/s10286-020-00727-9.

17. Kanjwal K, Jamal S, Kichloo A, Grubb BP. New-onset postural orthostatic tachycardia syndrome fol-lowing coronavirus disease 2019 infection. J Innov Card Rhythm Manag. 2020;11(11):4302-4. DOI:10.19102/icrm.2020.111102.

18. Taub PR, Zadourian A, Lo HC, et al. Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. J Am Coll Cardiol. 2021;77:861-71. DOI:10.1016/j.jacc.2020.12.029.

19. Shaw BH, Stiles LE, Bourne K, et al. The face of postural tachycardia syndrome - insights from a large cross-sectional online community-based survey. J Intern Med. 2019;286(4):438-48. DOI:10.1111/joim.12895.

20. Dani M, Dirksen A, Taraborrelli P, et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clin Med (Lond). 2021;21(1):e63-e67. DOI:10.7861/clinmed.2020-0896.

21. Vernino S, Stiles LE. Autoimmunity in postural orthostatic tachycardia syndrome: current understand-ing. Auton Neurosci. 2018;215:78-82. DOI:10.1016/j.autneu.2018.04.005.

22. Goldstein DS. The possible association between COVID-19 and postural tachycardia syndrome. Heart Rhythm. 2020;18(4):508-9. DOI:10.1016/j.hrthm.2020.12.007.

23. Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. Neurology. 2020;95(8):e1060-70. DOI:10.1212/WNL.0000000000009937.

24. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41:407-77. DOI:10.1093/eur-heartj/ehz425.

25. Ponikowski P, Voors AA, Anker SD, et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2129-200. DOI:10.1093/eurheartj/ehw128

26. Tahir F, Bin AT, Majid Z, et al. Ivabradine in Postural Orthostatic Tachycardia Syndrome: A Review of the Literature. Cureus. 2020;12(4):e7868. DOI:10.7759/cureus.7868.

27. Ruzieh M, Sirianni N, Ammari Z, et al. Ivabradine in the treatment of postural tachycardia syndrome (POTS), a single center experience. Pacing Clin Electrophysiol. 2017;40:1242-5. DOI:10.1111/pace.13182.

28. Sutton R, Salukhe TV, Franzen-Mcmanus AC, et al. Ivabradine in treatment of sinus tachycardia medi-ated vasovagal syncope. Europace. 2014;16:284-8. DOI:10.1093/europace/eut226.

29. McDonald C, Frith J, Newton JL. Single centre experience of ivabradine in postural orthostatic tachy-cardia syndrome. Europace. 2011;13:427-30. DOI:10.1093/europace/euq390.

30. Barzilai M, Jacob G. The effect of ivabradine on the heart rate and sympathovagalbalance in postural tachycardia syndrome patients. Rambam Maimonides Med J. 2015;6:e0028. DOI:10.5041/RMMJ.10213.

31. Donne GD, Noguer FR, Till J, et al. Ivabradine in postural orthostatic tachycardia syndrome: preliminary experience in children. Am J Cardiovasc Drugs. 2018;18:59-63. DOI:10.1007/s40256-017-0248-x.

32. Taub PR, Zadourian A, Lo HC, et al. Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. J Am Coll Cardiol. 2021;77(7):861-71. DOI:10.1016/j.jacc.2020.12.029.

33. Raj SR, Sheldon RS. Higher Quality Evidence to Guide Our Management of Postural Orthostatic Tachycardia SyndromeA New Era? J Am Coll Cardiol. 2021;77(7):872-4. DOI:10.1016/j.jacc.2020.12.028.

34. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021-104. DOI:10.1093/eurheartj/ehy339.


For citation:


Podzolkov V.I., Bragina A.E., Tarzimanova A.I., Vasil'eva L.V., Batrakova E.P., Lobova N.V., Bykova E.E., Khachuroeva M.M. Post-COVID Syndrome and Tachycardia: Theoretical Base and Treatment Experience. Rational Pharmacotherapy in Cardiology. 2021;17(2):256-262. (In Russ.) https://doi.org/10.20996/1819-6446-2021-04-08

Views: 1378


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)